WallStreetZenWallStreetZen

NASDAQ: APLM
Apollomics Inc Stock

Overview
EarningsRevenueDividendOwnership
$6.43+0.03 (+0.47%)
Updated Apr 29, 2025
APLM Price
$6.43
Fair Value Price
N/A
Market Cap
$7.09M
52 Week Low
$4.71
52 Week High
$44.89
P/E
-0.12x
P/B
1.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$53.86M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.69
Operating Cash Flow
-$28M
Beta
0.17
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

APLM Overview

Maxpro Capital Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets businesses in the financial services industry. Maxpro Capital Acquisition was incorporated in 2021 and is based in Taipei, Taiwan.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine APLM's potential to beat the market

View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

N/A
Value
N/A
Growth
N/A
Momentum
N/A
Sentiment
N/A
Safety
N/A
Financials
N/A
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
APLM
RankedUnranked of 462

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$2.96A
Aurinia Pharmaceuticals (AUPH)
$8.12A
Catalyst Pharmaceuticals (CPRX)
$24.28A
View Top Biotech Stocks

Be the first to know about important APLM news, forecast changes, insider trades & much more!

APLM News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how APLM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

APLM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
APLM is good value based on its book value relative to its share price (1.46x), compared to the US Biotechnology industry average (4.37x)
P/B vs Industry Valuation
APLM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more APLM due diligence checks available for Premium users.

Valuation

APLM fair value

Fair Value of APLM stock based on Discounted Cash Flow (DCF)

Price
$6.43
Fair Value
-$0.19
Undervalued by
3,465.10%
APLM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

APLM price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.12x
Industry
-158.75x
Market
29.19x

APLM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.46x
Industry
4.37x
APLM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

APLM's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
APLM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$13.1M
Liabilities
$8.2M
Debt to equity
1.69
APLM's short-term assets ($10.27M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APLM's short-term assets ($10.27M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APLM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
APLM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

APLM vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
APLM–$7.09M+0.47%-0.12x1.46x
BCLI–$7.08M-3.13%-0.47x-0.91x
XTLB–$7.14M-2.60%-4.37x3.22x
TRAWC$7.26M-5.92%-0.04x-0.23x
INDP–$6.78M-2.08%-0.29x1.72x
View Top Biotech Stocks

Apollomics Stock FAQ

What is Apollomics's quote symbol?

(NASDAQ: APLM) Apollomics trades on the NASDAQ under the ticker symbol APLM. Apollomics stock quotes can also be displayed as NASDAQ: APLM.

If you're new to stock investing, here's how to buy Apollomics stock.

What is the 52 week high and low for Apollomics (NASDAQ: APLM)?

(NASDAQ: APLM) Apollomics's 52-week high was $44.89, and its 52-week low was $4.71. It is currently -85.68% from its 52-week high and 36.52% from its 52-week low.

How much is Apollomics stock worth today?

(NASDAQ: APLM) Apollomics currently has 1,103,348 outstanding shares. With Apollomics stock trading at $6.43 per share, the total value of Apollomics stock (market capitalization) is $7.09M.

Apollomics stock was originally listed at a price of $1,011.00 in Oct 8, 2021. If you had invested in Apollomics stock at $1,011.00, your return over the last 3 years would have been -99.36%, for an annualized return of -81.47% (not including any dividends or dividend reinvestments).

How much is Apollomics's stock price per share?

(NASDAQ: APLM) Apollomics stock price per share is $6.43 today (as of Apr 29, 2025).

What is Apollomics's Market Cap?

(NASDAQ: APLM) Apollomics's market cap is $7.09M, as of Apr 30, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Apollomics's market cap is calculated by multiplying APLM's current stock price of $6.43 by APLM's total outstanding shares of 1,103,348.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.